within Pharmacolibrary.Drugs.ATC.C;

model C03CD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03CD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Muzolimine is a loop diuretic that was formerly used for the management of edema associated with congestive heart failure, cirrhosis, and renal disease, as well as for hypertension. Due to reports of severe neurotoxic side effects, including encephalopathy and irreversible hearing loss, muzolimine has been withdrawn from the market and is not currently approved for use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in adult human subjects; no peer-reviewed PK study identified in literature.</p><h4>References</h4><ol><li><p>Ritter, W, et al., &amp; Baykal, N (1985). Pharmacokinetics of muzolimine after oral administration with and without aluminium hydroxide in healthy volunteers. <i>Zeitschrift fur Kardiologie</i> 74 Suppl 2 149–151. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4002791/\">https://pubmed.ncbi.nlm.nih.gov/4002791</a></p></li><li><p>Brørs, O, et al., &amp; Arnesen, E (1979). Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. <i>European journal of clinical pharmacology</i> 15(2) 105–108. DOI:<a href=\"https://doi.org/10.1007/BF00609872\">10.1007/BF00609872</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/436918/\">https://pubmed.ncbi.nlm.nih.gov/436918</a></p></li><li><p>Brørs, O, et al., &amp; Jacobsen, S (1980). Pharmacokinetics and saluretic effect of muzolimine in severe cardiac failure. <i>Current medical research and opinion</i> 6(6) 431–436. DOI:<a href=\"https://doi.org/10.1185/03007998009109463\">10.1185/03007998009109463</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7363644/\">https://pubmed.ncbi.nlm.nih.gov/7363644</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03CD01;
